Drugs / AZD2284
last change Mar 2025 re-read 2 minutes ago

AZD2284

Developed for
castration-resistant prostate carcinoma
Investigated by
AstraZeneca · Parexel

Trials 1 · a red edge is where a trial was stopped

2026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06879041 Mar 2025 → Apr 2029 expected castration-resistant prostate carcinoma AstraZeneca Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as AZD2284 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06879041